MedWatch

Genmab and Novo Nordisk expand possible collaboration significantly

A collaboration on antibody development between the Danish companies Genmab and Novo Nordisk has been expanded, and this has given the biotech company two million dollars up front as well as the possibility of several more millions in milestone payments.

Foto: Genmab PR og /ritzau Scanpix/Stine Tidsvilde

In August 2015, the two life science-forerunners Novo Nordisk and Genmab entered a collaboration on antibody development, which can bring in the previously mentioned millions of dollars in milestone payments.

A few months ago, the two players expanded the collaboration, which has given Genmab a new two million dollar payment and the possibility of even larger milestone payments.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier